Cardiol Therapeutics Inc.: Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19
Oakville, Ontario (Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. (
Cardiol or the
Company ), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the formation of the Data Safety Monitoring Committee ( DSMC ) and the Clinical Endpoint Committee ( CEC ) for the Company s Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States.
The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial. In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group lev